Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study

Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease

(2009) Mahmut I. Yilmaz et al.   KIDNEY INTERNATIONAL

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

(2009) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erythropoietin, Iron Depletion, and Relative Thrombocytosis: A Possible Explanation for Hemoglobin-Survival Paradox in Hemodialysis

(2008) Elani Streja et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Exploring Relative Mortality and Epoetin Alfa Dose Among Hemodialysis Patients

(2008) Brian D. Bradbury et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Greater Epoetin alfa Responsiveness Is Associated With Improved Survival in Hemodialysis Patients

(2008) R. D. Kilpatrick et al.   Clinical Journal of the American Society of Nephrology

Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes

(2008) Lynda A. Szczech et al.   KIDNEY INTERNATIONAL

Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER--a multicentre, prospective, observational cohort study

(2008) R. Perez-Garcia et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Hemoglobin Level Variability: Associations with Mortality

(2007) D. T. Gilbertson et al.   Clinical Journal of the American Society of Nephrology